Mengxing Xue
Soochow University(CN)First Affiliated Hospital of Soochow University(CN)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, Acute Lymphoblastic Leukemia research, Retinoids in leukemia and cellular processes
Most-Cited Works
- → Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials(2020)26 cited
- → Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts(2019)20 cited
- → Low‐dose cytarabine and aclarubicin combined with granulocyte colony‐stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients(2013)16 cited
- → The Role of Interleukin-15 Polymorphisms in Adult Acute Lymphoblastic Leukemia(2010)16 cited
- → Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial(2024)14 cited
- → Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)(2021)11 cited
- → Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation(2022)10 cited
- → Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients(2019)7 cited
- → Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia(2024)6 cited
- [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].(2008)